Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy
- PMID: 17337114
- DOI: 10.1016/j.eururo.2007.02.041
Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy
Abstract
Objectives: To determine the prostate cancer incidence, anatomic distribution, Gleason score profile, and tumor burden in patients diagnosed by transperineal template-guided saturation biopsy (TTSB).
Materials and methods: One hundred and two patients underwent TTSB; all but one patient had undergone at least one prior negative TRUS biopsy. Criteria for inclusion included an elevated PSA and/or the diagnosis of ASAP or high-grade PIN on prior biopsy. The prostate gland was divided into 24 regional biopsy locations. The median number of biopsy cores was 50. Multiple clinical parameters were evaluated as predictors for prostate cancer diagnosis.
Results: The mean patient age was 64.8 yr with a mean PSA of 9.1 ng/ml and a prostate volume of 78.6 cm(3). On average, patients had undergone 2.1 prior negative TRUS biopsies with a mean of 22.4 core biopsies. Prostate cancer was diagnosed in 43 patients (42.2%) with a Gleason score distribution of 6-9. No anatomic region of the prostate gland was spared of cancer. In patients with prostate cancer, an average of 9.9 cores were involved. In multivariate analysis, prostate volume was the best predictor for prostate cancer diagnosis.
Conclusions: TTBS diagnosed prostate cancer in 42.2% of patients. Considerable anatomic variability in prostate cancer distribution was documented. On the basis of this and other reports, cancer eradication will depend on treatment of the entire prostate gland.
European Association of Urology
Comment in
-
Editorial comment on: prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.Eur Urol. 2007 Sep;52(3):723-4. doi: 10.1016/j.eururo.2007.02.042. Eur Urol. 2007. PMID: 17337115 No abstract available.
Similar articles
-
Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.Urology. 2009 Jul;74(1):171-6. doi: 10.1016/j.urology.2008.12.013. Epub 2009 Feb 20. Urology. 2009. PMID: 19232691
-
Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.J Urol. 2008 Oct;180(4):1325-9; discussion 1329. doi: 10.1016/j.juro.2008.06.022. Epub 2008 Aug 15. J Urol. 2008. PMID: 18707706
-
Editorial comment on: prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.Eur Urol. 2007 Sep;52(3):723-4. doi: 10.1016/j.eururo.2007.02.042. Eur Urol. 2007. PMID: 17337115 No abstract available.
-
The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.BJU Int. 2009 Mar;103(6):730-3. doi: 10.1111/j.1464-410X.2008.08205.x. Epub 2009 Jan 14. BJU Int. 2009. PMID: 19154475 Review.
-
Prostate cancer: is the PSA test the answer?N J Med. 1998 Mar;95(3):53-5. N J Med. 1998. PMID: 16013148 Review. No abstract available.
Cited by
-
[Prostate biopsy. Update for indication, procedure, and future developments].Urologe A. 2014 Jul;53(7):1046-51. doi: 10.1007/s00120-014-3536-y. Urologe A. 2014. PMID: 25023240 Review. German.
-
Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.Biomed Opt Express. 2015 Nov 9;6(12):4781-9. doi: 10.1364/BOE.6.004781. eCollection 2015 Dec 1. Biomed Opt Express. 2015. PMID: 26713193 Free PMC article.
-
Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting.Prostate Cancer Prostatic Dis. 2010 Mar;13(1):71-7. doi: 10.1038/pcan.2009.42. Epub 2009 Sep 29. Prostate Cancer Prostatic Dis. 2010. PMID: 19786982 Free PMC article.
-
HistoScanningTM to Detect and Characterize Prostate Cancer-a Review of Existing Literature.Curr Urol Rep. 2017 Oct 24;18(12):97. doi: 10.1007/s11934-017-0747-y. Curr Urol Rep. 2017. PMID: 29064054 Review.
-
When prostate cancer remains undetectable: The dilemma.Turk J Urol. 2015 Mar;41(1):32-8. doi: 10.5152/tud.2015.91249. Turk J Urol. 2015. PMID: 26328196 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous